Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

April 24, 2026 updated by: Goldman, Butterwick, Fitzpatrick and Groff

A Prospective, Single Center, Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonists

The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imaging, and reported adverse reactions.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Enrolled subjects will be in one of two groups, they will apply a topical serum (AGE Serum) to the full face and neck twice daily for 12 weeks. Subject follow-up visits will occur at Week 6 and Week 12. Subjects will complete assessments and participate in and standardized 2D and 3D (Visia) digital photography.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)
  2. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
  3. Adult women aged 45-65 years.
  4. Fitzpatrick skin types I-VI.
  5. Current treatment with a stable dose of any GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least the last 3 months
  6. Must be willing to sign a photography release and ICF,and complete the entire course of the study.
  7. Subjects in good general health based on the investigator's judgment and medical history.

Exclusion Criteria:

  1. Non post-menopausal state.
  2. Any uncontrolled systemic disease.
  3. History of autoimmune connective tissue disease.
  4. Current use of immunosuppressive medication.
  5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  6. Active dermatitis or active infection in the proposed treatment area.
  7. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
  8. Microneedling treatments of the face and neck during the 1 month period before study treatment
  9. Laser and light based device treatments of the face and neck. Ablative lasers 6-month period before study treatment, and 3-month period for non-ablative lasers.
  10. Any neurotoxin injection to the face or neck during the 6-month period before study treatment
  11. Subjects using any treatment skincare products must discontinue use of these products 2 weeks before the start of participating in this clinical study and for the duration of the study.
  12. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.
  13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.
  14. History of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, history of smoking.
  15. Inability to ambulate following the procedure.
  16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A= On GLP1 plus HRT
Enrolled subjects will receive AGE Serum.
Drug: On GLP1 plus HRT
AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.
Sham Comparator: Group B= On GLP1 Only
Enrolled subject will receive AGE serum
Drug: On GLP1 Only
AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Griffith Scale
Time Frame: Baseline, Week 6 and Week12

Modified Griffiths 10-point scale to be used for investigator grading of cutaneous signs of photoaging on the face.

Global Fine Lines. Scale 0 (no fine lines) to 9 (numerous, many fine lines) Overall Hyperpigmentation: Scale 0 (no hyperpigmentation) to 9 (significant hyperpigmentation) Skin Tone Eveness: Scale 0 (very even tone) to 9 (uneven, discolored appearance) Skin Elasticity: Score 0 (skin feels toned and dense) to 9 (skin feels thin and flabby) Skin Firmness: Score 0 (firm, tight feeling) to 9 (loose, lax feeling) Skin Radiance: Score 0 (very radiant, luminous, glowing) to 9 (very dull) Skin Texture: Score 0 (very smooth) to 9 (very rough)
Baseline, Week 6 and Week12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physician Global Aesthetic Improvement Scale
Time Frame: Week 12

Physician Grading:

  1. Very Much Improved
  2. Much Improved
  3. Improved
  4. No Change
  5. Worse
Week 12
Subject Global Aesthetic Improvement Scale
Time Frame: Week 12

Subject Grading:

  1. Very Much Improved
  2. Much Improved
  3. Improved
  4. No Change
  5. Worse
Week 12
Subject Self-Assessment Questionnaire
Time Frame: Baseline, Week 6 and Week 12

Circle One

Skin Feels More Comfortable:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Skin Appears Younger Looking:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Skin Appears Healthier:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Skin Looks Renewed/Revitalized:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Skin Looks Firmer:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Skin Feels Elastic :

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Redness Looks Reduced:

Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly
Baseline, Week 6 and Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff

Collaborators

L'Oreal

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 20, 2026

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

April 24, 2026

First Submitted That Met QC Criteria

April 24, 2026

First Posted (Actual)

April 30, 2026

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 24, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AGE-SERUM-2025-WAVE2

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Laxity; Skin

Clinical Trials on On GLP1 plus HRT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe